Skip to Main Content

Good morning everyone, hope you’re savoring the fresh start that comes with the beginning of the week. This is Rachel Cohrs sitting in today. Our morning cup of stimulation comes in the form of a steaming mug of English breakfast tea, as your author isn’t much of a coffee drinker — hopefully Ed will forgive the departure from canon. Here are a few items to help you catch up this Monday, and as always, stay in touch. …

Pfizer (PFE) will buy cancer-drug developer Trillium Therapeutics (TRIL) in a deal that values the company at $2.26 billion, Reuters reports. Trillium develops drugs that boost patients’ immune systems to fight off cancer cells, and its two leading candidates focus on blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment